Response Genetics Inc (RGDXQ)

Response Genetics, Inc. is a healthcare company focused on pharmacogenomic testing for cancer treatment. The company develops, markets, and sells tests that assess predictive factors for therapy response using tumor tissue samples, serving patients and clinicians in the United States, Europe, and other international markets. Its test offerings cover several cancer types, including non-small cell lung, colorectal, gastric and gastroesophageal, melanoma, thyroid, breast, and glioma, as well as tissue-of-origin analysis. Response Genetics also provides technical and professional testing components and develops additional tests for other tumor types. The company markets its services to community oncologists, pathologists, physician offices, hospitals, and pharmaceutical companies through its sales force. Founded in 1999 and headquartered in Los Angeles, California, it was previously known as Bio Type, Inc. before adopting its current name in 2000.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.